NSE - Delayed Quote INR

Torrent Pharmaceuticals Limited (TORNTPHARM.NS)

Compare
3,274.45
-47.10
(-1.42%)
At close: January 10 at 3:29:57 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
110,323,100.00
105,623,100.00
94,636,900.00
84,188,000.00
78,862,300.00
Cost of Revenue
28,497,300.00
27,877,300.00
28,276,900.00
25,374,700.00
22,353,000.00
Gross Profit
81,825,800.00
77,745,800.00
66,360,000.00
58,813,300.00
56,509,300.00
Operating Expense
53,862,300.00
52,022,300.00
44,959,800.00
41,119,900.00
38,281,600.00
Operating Income
27,963,500.00
25,723,500.00
21,400,200.00
17,693,400.00
18,227,700.00
Net Non Operating Interest Income Expense
-2,870,800.00
-3,420,800.00
-3,186,600.00
-2,479,100.00
-3,478,700.00
Pretax Income
25,791,100.00
23,521,100.00
18,471,600.00
12,259,100.00
15,262,600.00
Tax Provision
7,767,300.00
6,957,300.00
6,019,300.00
4,487,300.00
2,743,800.00
Net Income Common Stockholders
18,023,800.00
16,563,800.00
12,452,300.00
7,771,800.00
12,518,800.00
Diluted NI Available to Com Stockholders
18,023,800.00
16,563,800.00
12,452,300.00
7,771,800.00
12,518,800.00
Basic EPS
53.25
48.94
36.79
22.96
36.99
Diluted EPS
53.25
48.94
36.79
22.96
36.99
Basic Average Shares
338,465.06
338,445.44
338,445.44
338,445.44
338,445.44
Diluted Average Shares
338,465.06
338,445.44
338,445.44
338,445.44
338,445.44
Total Expenses
82,359,600.00
79,899,600.00
73,236,700.00
66,494,600.00
60,634,600.00
Net Income from Continuing & Discontinued Operation
18,023,800.00
16,563,800.00
12,452,300.00
7,771,800.00
12,518,800.00
Normalized Income
17,371,225.10
15,906,218.04
12,205,781.63
10,781,968.60
12,394,949.80
Interest Income
--
114,800.00
147,800.00
71,500.00
50,700.00
Interest Expense
2,976,300.00
3,526,300.00
3,322,400.00
2,529,300.00
3,508,200.00
Net Interest Income
-2,870,800.00
-3,420,800.00
-3,186,600.00
-2,479,100.00
-3,478,700.00
EBIT
28,767,400.00
27,047,400.00
21,794,000.00
14,788,400.00
18,770,800.00
EBITDA
36,750,400.00
35,000,400.00
28,814,300.00
21,407,700.00
25,343,900.00
Reconciled Cost of Revenue
28,497,300.00
27,877,300.00
28,276,900.00
25,374,700.00
22,353,000.00
Reconciled Depreciation
7,983,000.00
7,953,000.00
7,020,300.00
6,619,300.00
6,573,100.00
Net Income from Continuing Operation Net Minority Interest
18,023,800.00
16,563,800.00
12,452,300.00
7,771,800.00
12,518,800.00
Total Unusual Items Excluding Goodwill
933,800.00
933,800.00
365,700.00
-4,747,900.00
151,000.00
Total Unusual Items
933,800.00
933,800.00
365,700.00
-4,747,900.00
151,000.00
Normalized EBITDA
35,816,600.00
34,066,600.00
28,448,600.00
26,155,600.00
25,192,900.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
281,225.10
276,218.04
119,181.63
-1,737,731.40
27,149.80
3/31/2021 - 7/1/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HESTERBIO.NS Hester Biosciences Limited
2,264.20
-3.48%
 
ALKEM.BO Alkem Laboratories Limited
5,372.50
-1.39%
 
INDOCO.NS Indoco Remedies Limited
327.80
-1.90%
 
SOLARA.NS Solara Active Pharma Sciences Limited
654.70
-4.07%
 
AARTIDRUGS.NS Aarti Drugs Limited
429.95
-2.78%
 
DRREDDY.BO Dr. Reddy's Laboratories Limited
1,354.20
-1.27%
 
GUFICBIO.NS Gufic Biosciences Limited
468.40
+1.68%
 
LUPIN.BO Lupin Limited
2,190.50
-2.72%
 
HIKAL.NS Hikal Limited
358.05
-3.66%
 
MANKIND.NS Mankind Pharma Limited
2,739.95
-3.12%